Compare Quest Diagnostics Inc (DGX) vs SanDisk (SNDK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs SanDisk — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while SanDisk trades at $1,581.82 (market cap $232.61B). The key difference: SanDisk is far larger — about 9.1× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while SanDisk pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and SanDisk for 8 Days on average.
| DGX | SNDK | |
|---|---|---|
Market Cap | $25.48B | $232.61B |
Volume | 941,866 | 9,218,054 |
Sector | Health | Technology |
52-Week High | $247.45 | $2.34K |
52-Week Low | $173.49 | $116.91 |
Typical Hold Time | 56 Days | 8 Days |
Enterprise Value | $31.23B | $228.03B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
SNDK trades at $1,581.82, down 6.54% amid recent volatility, yet maintains strong analyst support with 87.5% buy ratings and a $2,160 consensus price target. The stock shows exceptional profitability metrics including 71.47% gross margins and 91.64% ROE, though current earnings reflect a net loss of -$1.64B for 2025. Recent news highlights institutional positioning shifts and AI-driven memory demand dynamics affecting performance.
Outlook remains cautiously optimistic given projected 2026 revenue growth to $20.2B and net profit of $11.4B, but risks include memory cycle volatility and competitive pressures. Technical indicators suggest near-term bearish pressure with key support at $1,575, while fundamental strength in profitability metrics supports long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About SanDisk
Sandisk is a semiconductor memory company specializing in NAND flash technology. Its storage products support consumer devices, enterprise systems, and cloud and AI infrastructure.
Read more on SNDK →
